ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 168

Predicting The Severity Of Joint Damage In Rheumatoid Arthritis; The Contribution Of Genetic Factors

Hanna W. van Steenbergen1, Roula Tsonaka2, Tom W.J. Huizinga1, Saskia le Cessie2,3 and Annette H.M. van der Helm-van Mil1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Medical Statistics, Leiden University Medical Center, Leiden, Netherlands, 3Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Genetics and joint damage

  • Tweet
  • Email
  • Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Background/Purpose: The severity of radiologic progression is variable between rheumatoid arthritis (RA) patients. Recently several genetic severity variants have been identified and replicated. This study determined the contribution of the established genetic severity factors to the explained variance in radiologic progression and evaluated whether genetic factors, in addition to traditional clinical and serological risk factors, improved the accuracy of predicting the severity of radiologic progression.

Methods: 417 early RA patients with yearly radiologic follow up were studied. The main outcome measure was the progression in Sharp-van der Heijde scores (SHSs) over six years. Genetic variants in the following genes were studied: HLA-DRB1, CD40, IL-15, DKK-1, IL2RA, GRZB, IL-4R, SPAG16, C5orf30, MMP-9 and OPG.  Linear regression analyses were used to determine the explained variance and the net improvement in reclassifications of prediction models without and with genetic risk factors. For studying reclassification, the continuous outcome was categorized based on the severity of radiologic progression in progression in SHSs over six years ≤6, 7-30 and >30 units, indicating mild, moderate and severe radiologic progression.

Results: Treatment effects and a combination of traditional risk factors explained 7.1% and 31.2% of the variance in progression in SHSs over six years. The genetic factors together explained 18.1%. When added to treatment effects and traditional factors, the genetic risk factors additionally explained 7.4% of the variance. Compared to a prediction model without genetic factors, a prediction model also including genetic factors yielded a net correct reclassification of 5.9% of the patients; now 62% of those patients were correctly classified.  Thus with a model including known traditional and genetic factors 38.1% of the patients were still not correctly classified. Evaluating the reclassifications per severity group, the net percentages of patients that were additionally correctly classified were 0%, 5.1% and 13.2% for the groups with mild, moderate and severe progression respectively. Hence, including genetic factors led to improved identification of patients with severe radiological progression in particular. Sensitivity analyses using imputation of missing radiographs yielded comparable results.

Conclusion: When added to a model consisting of traditional factors, genetic risk factors improved the predictive accuracy. Nonetheless, the predictive performance was still insufficient for use in clinical practice.


Disclosure:

H. W. van Steenbergen,
None;

R. Tsonaka,
None;

T. W. J. Huizinga,
None;

S. le Cessie,
None;

A. H. M. van der Helm-van Mil,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predicting-the-severity-of-joint-damage-in-rheumatoid-arthritis-the-contribution-of-genetic-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology